Soligenix Inc (SNGX):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C10117)
◆英語タイトル:Soligenix Inc (SNGX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10117
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:77
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥32,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥64,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥96,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Soligenix Inc (Soligenix) is a late-stage biopharmaceutical company which focuses on the development of products for the treatment of serious inflammatory diseases and biodefense counter measures. It develops biotherapeutics for the treatment of orphan diseases such as cutaneous T-cell lymphoma, pediatric Crohn’s disease, oral mucositis and acute radiation enteritis. It develops proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the treatment of gastrointestinal disorders that are characterized by high inflammation, including pediatric Crohn’s disease, acute radiation enteritis and oral mucositis. The company has active development programs for RiVax, a ricin toxin vaccine; VeloThrax, an anthrax vaccine; and OrbeShield, a gastrointestinal acute radiation syndrome therapeutic. These vaccine programs are supported by ThermoVax, a heat stabilization technology. Soligenix is headquartered in Princeton, New Jersey, the US.

Soligenix Inc (SNGX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Soligenix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Soligenix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Soligenix Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Soligenix Acquires SGX301 from Hy Biopharma for USD14 Million 12
Soligenix Acquires SGX94 from Inimex Pharma 14
Venture Financing 15
Soligenix Raises USD2 Million in Venture Financing 15
Partnerships 16
Soligenix Enters into Co-Development Agreement with University of Hawaii at Manoa and Hawaii Biotech 16
Soligenix Expands its Development Agreement with Emergent BioSolutions 17
Soligenix Enters into Contract with National Institute of Allergy and Infectious Diseases and Biomedical Advanced Research and Development Authority 18
Soligenix Enters Into Co-Marketing Agreement With SciClone Pharma For SGX942 19
Soligenix Enters Into Co-Development Agreement With Intrexon 20
Soligenix Enters Into Agreement With Infectious Disease Research Institute To Develop Biodefense Vaccines 21
Licensing Agreements 23
SciClone Pharma Enters into Licensing Agreement with Soligenix 23
Soligenix Enters into Licensing Agreement with New York University and Yeda Research and Development 24
Soligenix Enters Into Licensing Agreement With Intrexon To Develop Melioidosis Therapy 25
Equity Offering 27
Soligenix to Raise up to USD9 Million in Public Offering of Shares 27
Soligenix Raises USD8 Million in Public Offering of Shares and Warrants 28
Soligenix Plans to Raise up to USD2.16 Million in Private Placement of Shares 30
Soligenix Raises USD3.2 Million in Public Offering of Shares 31
Soligenix Raises USD2 Million in Private Placement of Shares 32
Soligenix Raises USD5.3 Million in Public Offering of Shares and Warrants 33
Soligenix to Raise USD12 Million in Private Placement of Shares 35
Soligenix Raises USD2.3 Million in Public Offering of Shares 36
Soligenix Completes First Tranche Of Private Placement Of Shares For US$0.6 Million 38
Soligenix Completes Private Placement Of Units For US$7 Million 39
Soligenix Inc – Key Competitors 40
Soligenix Inc – Key Employees 41
Soligenix Inc – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
Aug 08, 2018: Soligenix announces recent accomplishments and second quarter 2018 financial results 43
May 11, 2018: Soligenix Announces Recent Accomplishments And First Quarter 2018 Financial Results 44
Mar 15, 2018: Soligenix Announces Recent Accomplishments And Year-End 2017 Financial Results 45
Nov 06, 2017: Soligenix Announces Recent Accomplishments And Third Quarter 2017 Financial Results 46
Aug 11, 2017: Soligenix Announces Recent Accomplishments And Second Quarter 2017 Financial Results 47
May 11, 2017: Soligenix Announces Recent Accomplishments And First Quarter 2017 Financial Results 49
Mar 27, 2017: Soligenix Announces Recent Accomplishments And Year-End 2016 Financial Results 51
Corporate Communications 53
Jul 24, 2018: Soligenix announces appointment of mark pearson to its board of directors 53
Government and Public Interest 54
Jul 19, 2018: Soligenix driving towards key inflection points with two pivotal phase 3 clinical trials 54
Product Approvals 56
Feb 02, 2017: Soligenix Announces SGX301 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency 56
Jan 05, 2017: Soligenix Receives Positive Scientific Advice from the European Medicines Agency for SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer Patients 57
Clinical Trials 58
Jun 04, 2018: Soligenix Announces Poster at the 2018 American Society of Microbiology Microbe Conference in Atlanta, Georgia 58
Jan 02, 2018: Soligenix Announces US Patent Issuance for Use of Dusquetide in Oral Mucositis 60
Nov 27, 2017: Soligenix Announces Presentation of Data on Dusquetide at Chemical and Biological Defense Science and Technology Conference 62
Oct 24, 2017: Broad-Spectrum Innate Defense Regulator Platform Technology to be Presented at the Peptide Therapeutics Foundation Symposium 63
Oct 05, 2017: Dusquetide Technology Platform to be Presented at the 2nd World Congress and Expo on Immunology 65
Jul 27, 2017: Soligenix Initiates Pivotal Phase 3 Clinical Trial of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 67
Jun 19, 2017: Complete Efficacy and Long-Term Follow-Up Safety Results from SGX942 Phase 2 Oral Mucositis Clinical Trial to be Presented at the 2017 Multinational Association for Supportive Care in Cancer Conference 69
May 18, 2017: Soligenix Announces Publication Of Its Phase 2 Long-term Follow-up Results Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients 71
May 03, 2017: Soligenix Receives FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 73
Other Significant Developments 74
Jan 25, 2018: Soligenix – Driving Towards Key Inflection Points with Two Pivotal Phase 3 Clinical Trials 74
Appendix 77
Methodology 77
About GlobalData 77
Contact Us 77
Disclaimer 77

List of Tables
Soligenix Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Soligenix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Soligenix Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Soligenix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Soligenix Acquires SGX301 from Hy Biopharma for USD14 Million 12
Soligenix Acquires SGX94 from Inimex Pharma 14
Soligenix Raises USD2 Million in Venture Financing 15
Soligenix Enters into Co-Development Agreement with University of Hawaii at Manoa and Hawaii Biotech 16
Soligenix Expands its Development Agreement with Emergent BioSolutions 17
Soligenix Enters into Contract with National Institute of Allergy and Infectious Diseases and Biomedical Advanced Research and Development Authority 18
Soligenix Enters Into Co-Marketing Agreement With SciClone Pharma For SGX942 19
Soligenix Enters Into Co-Development Agreement With Intrexon 20
Soligenix Enters Into Agreement With Infectious Disease Research Institute To Develop Biodefense Vaccines 21
SciClone Pharma Enters into Licensing Agreement with Soligenix 23
Soligenix Enters into Licensing Agreement with New York University and Yeda Research and Development 24
Soligenix Enters Into Licensing Agreement With Intrexon To Develop Melioidosis Therapy 25
Soligenix to Raise up to USD9 Million in Public Offering of Shares 27
Soligenix Raises USD8 Million in Public Offering of Shares and Warrants 28
Soligenix Plans to Raise up to USD2.16 Million in Private Placement of Shares 30
Soligenix Raises USD3.2 Million in Public Offering of Shares 31
Soligenix Raises USD2 Million in Private Placement of Shares 32
Soligenix Raises USD5.3 Million in Public Offering of Shares and Warrants 33
Soligenix to Raise USD12 Million in Private Placement of Shares 35
Soligenix Raises USD2.3 Million in Public Offering of Shares 36
Soligenix Completes First Tranche Of Private Placement Of Shares For US$0.6 Million 38
Soligenix Completes Private Placement Of Units For US$7 Million 39
Soligenix Inc, Key Competitors 40
Soligenix Inc, Key Employees 41
Soligenix Inc, Subsidiaries 42

List of Figures
Soligenix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Soligenix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Soligenix Inc (SNGX):製薬・医療:M&Aディール及び事業提携情報(Soligenix Inc (SNGX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆